GR1008168B - Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof - Google Patents

Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof

Info

Publication number
GR1008168B
GR1008168B GR20130100156A GR20130100156A GR1008168B GR 1008168 B GR1008168 B GR 1008168B GR 20130100156 A GR20130100156 A GR 20130100156A GR 20130100156 A GR20130100156 A GR 20130100156A GR 1008168 B GR1008168 B GR 1008168B
Authority
GR
Greece
Prior art keywords
preparation
antibacterial agent
parenteral formulation
fluoroquinolone antibacterial
formulation
Prior art date
Application number
GR20130100156A
Other languages
Greek (el)
Inventor
Ευαγγελος Ανδρεα Καραβας
Ευθυμιος Χρηστου Κουτρης
Ιωαννα Χρηστου Κουτρη
Αθηνα Γεωργιου Ηλιοπουλου
Βασιλικη Χρηστου Σαμαρα
Μορφης Νικολαου Αμπατζης
Γεωργιος Θεμιστοκλη Γκοτζαμανης
Original Assignee
"Φαρματεν Α.Β.Ε.Ε.",
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "Φαρματεν Α.Β.Ε.Ε.", filed Critical "Φαρματεν Α.Β.Ε.Ε.",
Priority to GR20130100156A priority Critical patent/GR1008168B/en
Priority to PCT/EP2014/000668 priority patent/WO2014139677A1/en
Priority to EP14722987.6A priority patent/EP2976063A1/en
Publication of GR1008168B publication Critical patent/GR1008168B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an aqueous pharmaceutical formulation of Moxifloxacin or a pharmaceutically acceptable salt thereof and propylene glycol to be used for the treatment of infections in humans or animals. The present invention also provides a method of preparation of such formulation.
GR20130100156A 2013-03-14 2013-03-14 Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof GR1008168B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GR20130100156A GR1008168B (en) 2013-03-14 2013-03-14 Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
PCT/EP2014/000668 WO2014139677A1 (en) 2013-03-14 2014-03-13 Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
EP14722987.6A EP2976063A1 (en) 2013-03-14 2014-03-13 Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20130100156A GR1008168B (en) 2013-03-14 2013-03-14 Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof

Publications (1)

Publication Number Publication Date
GR1008168B true GR1008168B (en) 2014-04-08

Family

ID=50687438

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20130100156A GR1008168B (en) 2013-03-14 2013-03-14 Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof

Country Status (3)

Country Link
EP (1) EP2976063A1 (en)
GR (1) GR1008168B (en)
WO (1) WO2014139677A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026110A1 (en) * 1993-05-15 1994-11-24 Abbott Laboratories Stable quinolone and naphthyridine premix formulations
JPH0782141A (en) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd Injection for animal
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
US20090163484A1 (en) * 2006-03-08 2009-06-25 Bayer Animal Health Gmbh Pharmaceuticals containing fluoroquinolones
EP2078527A1 (en) * 2006-10-12 2009-07-15 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid preparation comprising gatifloxacin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (en) 1988-07-15 1990-01-18 Bayer Ag 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM
DE19937116A1 (en) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin saline formulation
ATE243038T1 (en) 1999-11-01 2003-07-15 Alcon Inc PHARMACEUTICAL COMPOSITIONS CONTAINING A FLUOROCHINOLONE ANTIBIOTIC AND XANTHANG GUM
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
EP2049112B1 (en) * 2006-08-07 2012-03-14 Bausch & Lomb Incorporated Treating infections and sequelae thereof with combined dissociated glucocorticoid receptor agonists and anti-infective agents
BRPI0818483A2 (en) * 2007-11-01 2015-04-14 Bausch & Lomb Method for preparing a pharmaceutical composition, pharmaceutical composition, and use thereof.
US20110319502A1 (en) * 2010-06-25 2011-12-29 Coffey Martin J Compositions and Methods for Enhancing Reduction of Spore-Forming Microorganisms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026110A1 (en) * 1993-05-15 1994-11-24 Abbott Laboratories Stable quinolone and naphthyridine premix formulations
JPH0782141A (en) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd Injection for animal
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
US20090163484A1 (en) * 2006-03-08 2009-06-25 Bayer Animal Health Gmbh Pharmaceuticals containing fluoroquinolones
EP2078527A1 (en) * 2006-10-12 2009-07-15 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid preparation comprising gatifloxacin

Also Published As

Publication number Publication date
EP2976063A1 (en) 2016-01-27
WO2014139677A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IL257481B (en) Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof
HK1250714A1 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
HK1232120A1 (en) Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
PH12015502013A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12015501957A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
EP2987786A4 (en) Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component
HK1208378A1 (en) Pharmaceutical composition for the treatment of fungal infections
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
PL3103453T3 (en) Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP3085369A4 (en) Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain
GR1008186B (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
GR1008168B (en) Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
EP3082766A4 (en) Liquid formulation comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing same
MX360040B (en) Novel phenicol antibacterial agents.
PH12016502548A1 (en) Antimicrobial compositions with effervescent agents
GR1008169B (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
GR1008258B (en) Ophthalmic formulation of fluoroquinolone antibacterial agent and method for preparation thereof
ZA201304316B (en) Ophthalmic formulation of fluoroquinolone antibacterial agent and method for preparation thereof
UA91125U (en) Antibacterial composition
EP3101014A4 (en) Novel 2-phenylbenzofuran derivative or pharmaceutically acceptable salt thereof, production method for same and pharmaceutical composition for preventing or treating inflammatory disease comprising same as active ingredient
UA88315U (en) Antibacterial composition
IN2013MU01983A (en)
ZA201302189B (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20140515